by Johns Hopkins University School of Medicine The structure of alpha-synuclein clumps (on the left) was disrupted by the nanobody PFFNB2 (as shown on the right). Credit: Xiaobo Mao Proteins called antibodies help the immune system find and attack foreign pathogens. Mini versions of antibodies, called nanobodies—natural compounds in the blood of animals such as...
EMOTIVE (Vienna, Sunday, 26 June 2022) How long someone lives with Parkinson’s disease may be down to specific gene mutations, according to new research presented today at the 8thEuropean Academy of Neurology (EAN) Congress.1 Scientists from four institutes in Paris, including the prestigious Paris Brain Institute at the Sorbonne Université, studied the records of 2,037...
by Dirk Hoffman, University at Buffalo Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson’s disease. Credit: Wikipedia A new study led by a researcher in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo has important implications for developing future treatments for Parkinson’s...
by Johns Hopkins University School of Medicine Graphical abstract. Credit: Cell (2022). DOI: 10.1016/j.cell.2022.04.020 In studies in mice, Johns Hopkins Medicine researchers say they have identified a chemical compound that stops the final events in the pathway linked to the death of brain cells in Parkinson’s disease. Results of the experiments, they say, could advance the development...
UNIVERSITY OF ARIZONA Parkinson’s disease is perhaps best known for its movement-related symptoms, particularly tremors and stiffness. But the disease is also known to hinder vocal production, giving those with Parkinson’s a soft monotonous voice. Those symptoms, research has suggested, often appear much earlier in the disease’s development – sometimes decades before movement-related symptoms. New...
Kelli Whitlock Burton April 11, 2022 An experimental drug that combines fixed doses of extended-release (ER) formulations of existing medications can significantly reduce symptoms in patients with untreated early-stage Parkinson’s disease (PD), new research suggests. Results from a phase 3 trial of P2B001, a combination of pramipexole and rasagiline at currently unavailable low doses, showed...
Dr Alan Whone, Consultant Neurologist. holding a model of The Picostim™ DBS system. NEUROTECH APRIL 27, 2022 by Steve Fink A British hospital is the first in the world to implant a brain device that reverses the symptoms of Parkinson’s disease. Now, its test patient is gushing over the results and says he’s gotten his...
by Chinese Academy of Sciences Mitochondrial content decreased in dopaminergic neurons and astrocytes of mice treated with FNZ. (A to F) Immunostaining was used to detect mitochondria (TOM20) in the dopaminergic neurons (TH) of mice treated with FNZ for 2 weeks. Representative images of mitochondria in neurite (A) and cell body (D) are shown. Quantification...
by Olivia Miller, University of Kent Professor David Wilkinson. Credit: University of Kent Some of the most troubling features of Parkinson’s disease can be reduced by gentle stimulation of the balance organs via the application of electric or thermal currents to nearby parts of the head. This observation, made by Professor David Wilkinson at the...
Researchers seek to understand why some Parkinson’s patients’ symptoms briefly vanish. In one video, an elderly gentleman who normally can barely walk pedals a bike effortlessly down an Amsterdam street. In another video, a man who typically can’t hold a mug without sloshing the water out of it catches a ball as he jogs across the room and...
